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Abstract
Background: In osteoarthritis, chondrocytes adopt an abnormal hypertrophic morphology and upregulate the
expression of the extracellular matrix-degrading enzymes, MMP-13 and ADAMTS-5. The activation of the hedgehog
signalling pathway has been established in osteoarthritis and is thought to influence both of these processes.
However, the role of this pathway in the initiation and progression of osteoarthritis is unclear as previous studies
have been unable to isolate the effects of hedgehog pathway activation from other pathological processes. In this
study we test the hypothesis that hedgehog pathway activation causes cartilage degradation in healthy cartilage
and in an in vitro model of inflammatory arthritis.
Methods: Isolated articular chondrocytes from the bovine metacarpal-phalangeal joint were stimulated for up to
24 hours with the agonist, recombinant Indian hedgehog (r-Ihh). ADAMTS-5 and MMP-13 gene expression was
quantified by real-time PCR. In addition, healthy bovine cartilage explants were treated with r-Ihh or the hedgehog
antagonist, cyclopamine, and sGAG release into the media was measured over 72 hours. Studies were repeated using
chondrocytes and cartilage explants from human knee joint. Finally, studies were conducted to determine the effect of
hedgehog pathway activation on matrix catabolism in the presence of the pro-inflammatory cytokine, IL-1β.
Results: Addition of r-Ihh activated hedgehog signalling, confirmed by upregulation of Gli1 and Ptch1 expression, but
did not increase ADAMTS-5 or MMP-13 expression in bovine or human chondrocytes. Furthermore, r-Ihh did not induce
sGAG release in healthy bovine or human cartilage explants. IL-1β treatment induced sGAG release, but this response
was not altered by the stimulation or inhibition of hedgehog signalling. Hedgehog pathway activation was
downregulated by IL-1β. Conversely, r-Ihh weakly suppressed IL-1β-induced ADAMTS-5 expression.
Conclusion: Our results show for the first time that Indian hedgehog does not cause extracellular matrix degradation
in healthy ex vivo cartilage or in the presence of IL-1β and that IL-1β downregulates Indian hedgehog induced
signalling. Thus, we suggest reported hedgehog induced matrix catabolism in osteoarthritis must be due to its
interaction with pathological factors other than IL-1β. Hence, hedgehog signalling and its downstream effects are
highly context-dependent.
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Background
Osteoarthritis (OA), characterised by the progressive de-
generation of load-bearing diarthrodial joints, such as
the knees and hips, is one of the leading causes of dis-
ability worldwide. In OA, the metabolic balance between
extracellular matrix production and degradation is dis-
rupted, leading to increased catabolic breakdown of the
articular cartilage [1]. The mechanisms underlying OA
are not fully understood, however, previous research in-
dicates that disease progression is influenced by a com-
bination of factors including injury, metabolism, age,
and genetics [2]. Furthermore, strong evidence points to
a significant inflammatory component to OA, involving
cytokine cross-talk between chondrocytes, the synovium
lining the joint capsule and the underlying bone [3].
The hedgehog signalling pathway has also been impli-
cated in the pathogenesis of OA [4–6]. In articular cartilage,
hedgehog pathway activation requires the binding of Indian
hedgehog (Ihh) to its transmembrane receptor, Patched-1
(Ptch1). Ptch1 causes disinhibition of the transmembrane
protein Smoothened (Smo), enabling its enrichment and
activation in the primary cilium, a microtubule-based or-
ganelle found in most cells, including articular chondro-
cytes [7–9]. Smo indirectly activates the downstream Gli
transcription factors, which in turn translocate to the nu-
cleus to induce the expression of hedgehog target genes,
such as Ptch1 and Gli1 [7, 8, 10, 11]. Hedgehog signalling
regulates chondrocyte differentiation and proliferation dur-
ing embryonic skeletal development and in the terminal
growth plate [12, 13]. In OA, chondrocytes exhibit a pheno-
typic shift to a more terminal growth-plate-like state, adopt-
ing a similar hypertrophic morphology and upregulating
the expression of hypertrophic markers, including type X
collagen, matrix metalloproteinase (MMP)-13 and a
disintegrin and metalloproteinase with thrombospon-
din motifs (ADAMTS)-5 [14]. Hedgehog pathway activa-
tion is thought to contribute to this process. Indeed, Lin
et al. report that hedgehog pathway activation is increased
in both human and mouse OA cartilage, with higher levels
of hedgehog signalling correlating with increased disease
severity [5]. Moreover, hedgehog blockade reduces the ex-
pression of OA-related genes, including ADAMTS5 and
MMP13, in mice with surgically induced OA and in hu-
man OA cartilage samples [5, 6]. Further evidence for the
role of hedgehog pathway activation in OA stems from
the increased expression of Indian hedgehog (Ihh) in car-
tilage and synovial fluid in human OA, with a 5.2-fold and
a 1.71-fold increase, respectively, compared to their nor-
mal controls [4, 15].
Hedgehog pathway activation stimulates specific Gli2-
mediated expression of runt-related transcription factor 2
(Runx2) [16]. Runx2 upregulates several matrix-degrading
enzymes, including MMPs-1, 3, and 13 and ADAMTS-4
and ADAMTS-5, increases production of nitric oxide
(NO) and prostaglandin E2 (PGE2) and upregulates the ex-
pression of type X collagen. The Ihh-Runx2 pathway thus
represents a plausible mechanism by which the hedgehog
pathway influences OA development as Runx2 functions
upstream of many proteins identified in cartilage lesions
in early OA [5, 17, 18].
While hedgehog pathway activation has been demon-
strated to increase the likelihood of developing OA, the
nature of these studies prevent analysis of hedgehog
pathway activation in isolation from other processes that
occur within the complex environment of the joint. In
the current study we test if hedgehog pathway activation
alone can stimulate cartilage degradation in healthy hu-
man and bovine articular cartilage samples. We report
that pathway activation in response to Indian hedgehog
(Ihh) does not influence the expression of ADAMTS-5
or MMP-13, nor induce cartilage degradation, as mea-
sured by sulphated glycosaminoglycan (sGAG) release.
The response to hedgehog pathway activation was also
examined in an in vitro bovine model of inflammatory
arthritis. We report that neither stimulation nor inhib-
ition of the hedgehog pathway influenced cartilage deg-
radation in the presence of IL-1β. Thus, we conclude
that the catabolic effects of hedgehog signalling in OA
must arise due to interaction with other physiological or
pathological signalling pathways within the joint.
Methods
Reagents and media preparation
Chondrogenic media consisted of DMEM supple-
mented with 86 U/mL penicillin-streptomycin, 1.72 mM L-
glutamine, 17.25 mM HEPES, 0.12 mg/mL ascorbate, and
10 % FBS (Sigma-Aldrich, Poole, UK). Recombinant human
IL-1β (Peprotech, London, UK) stock solution consisted of
10 μg/mL in PBS containing 0.01 % BSA and 10 % FBS
[19]. Recombinant human/mouse Ihh (r-Ihh) stock solu-
tion consisted of 200 μg/mL in PBS containing 0.01 % BSA
(R&D Systems, Minneapolis, MN, USA). Cyclopamine
stock solution was 10 μM in ethanol (EMD Millipore, San
Diego, CA, USA). The effective doses and modes of action
of the pharmaceuticals used in this study are listed in
Table 1. The differences in the cyclopamine doses used for
bovine and human samples were based on previous find-
ings [20–24].
Chondrocyte isolation and culture
Primary bovine articular chondrocytes were isolated
from the metacarpophalangeal joints of 1–2-year-old
steers by enzymatic digestion as previously described
[25]. Human primary articular chondrocytes from the
tibial plateau of knee joints from three donors (one fe-
male and two male) aged 26–60 years, were purchased
from Articular Engineering (Northbrook, IL, USA) and
cultured without passage. Primary chondrocytes were
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plated at 80,000 cells per cm2 onto glass coverslips and
cultured in chondrogenic media for 5 days (confluence)
before treatment with 10 ng/mL IL-1β or r-Ihh (Table 1).
After treatment, cultures were processed for real-time
PCR as indicated below.
Cartilage explant model
Full-thickness human articular cartilage explants (3 ×
3 mm blocks) were harvested from macroscopically
healthy regions of the tibial plateau of a male patient
undergoing total joint arthroplasty for OA. The human
tissue was obtained with informed patient consent and full
National Health Service (NHS) ethical approval (East
London and The City Research Ethics Committee - Ethics
number: 07/Q0605/29). Full-thickness articular cartilage
explants (5 mm diameter) were harvested metacarpopha-
langeal joints from 1–2-year-old steers as previously de-
scribed [15]. Individual cartilage explants were then
placed in 24-well plates and cultured in 1 mL of their re-
spective experimental media as outlined in Table 1. The
culture media was collected and replaced every 24 hours
over the 72-hour culture period and stored at −20 °C for
biochemical assay. In the IL-1β-treated groups, the media
were further supplemented with 2.5 ng/mL or 10 ng/mL
IL-1β during the first 24 hours in culture.
Explant viability analysis
Following the 72-hour culture period, a cell viability assay
was performed on representative bovine explants from all
groups via LIVE/DEAD Cell Viability Assays (Molecular
Probes, Paisley, UK) and imaged on a confocal microscope
(Leica Microsystems, Wetzlar, Germany). The numbers of
viable and dead cells in each field of view were counted
using ImageJ (NIH, Bethesda, MD, USA) and used to cal-
culate the percentage cell viability for each group.
Sulphated glycosaminoglycan assay
Culture media was analysed using the 1,9-dimethylmethy-
lene blue (DMMB) assay to determine the amount of
sGAG released due to breakdown of the cartilage extracel-
lular matrix [26]. Each sample was run in triplicate against
a chondroitin sulfate standard curve (0–50 μg/mL). As all
samples were of similar weights and dimensions, the
sGAG release for each explant was normalized to the
mean sGAG release of the untreated explants at the same
time point to account for donor variability.
RNA extraction, cDNA synthesis, and real-time PCR
RNA was extracted from isolated chondrocyte culture and
converted to cDNA using the RNeasy and QuantiTect
Reverse Transcription Kits (Qiagen, Manchester, UK),
evaluated by gel electrophoresis, and quantified using
spectrophotometry. Quantitative real-time PCR was per-
formed as previously described [9]. The sequences of the
primers used in this experiment are shown in Table 2.
Fold-change in gene expression was calculated relative to
18S rRNA controls.
Statistical analysis
Statistical differences in gene expression, sGAG and cell
viability were measured using two-way analysis of variance
(ANOVA) with Tukey’s post hoc comparison (GraphPad,
Table 1 The doses and modes of actions of hedgehog pharmaceuticals
Drug name Molecular weight Mechanism of action Dose
r-Ihh 20,000 Da Binds to Ptch1, causing Ptch1 inhibition and Smo activation [5, 41] 1 μg/mL
Cyclopamine 411.6 Da Smo antagonist [20–24] Bovine: 10 μM
Human: 20 μM
KAAD-cyclopamine 698 Da Smo antagonist [24, 42, 43] 1 μM
SANT-1 373.5 Da Smo antagonist [20, 23, 44] 1 μM
GANT61 429.6 Da Gli antagonist [39, 45, 46] 10 μM
Ptch 1 patched 1, r-Ihh recombinant Indian hedgehog, Smo smoothened
Table 2 Primer sequences for the genes measured in this
experiment
Gene Species Sequence (5′-3′)




ADAMTS-5 Bovine F- GCCCTGCCCAGCTAACGGTA
R- CCCCCGGACACACACGGAA
MMP-13 Bovine F- CCCTTGATGCCATAACCAGT
R- GCCCAAAATTTTCTGCCTCT
18S rRNA Bovine F- GCAATTATTCCCCATGAACG
R- GGCCTCACTAAACCATCCAA
ADAMTS-5 Human F- CCTTGTGGAAAGGGGAGAAT
R- ACAGTGACGATAGGCAAACT
MMP-13 Human F- AGCCACTTTATGCTTCCTGA
R- TCAAACTGTATGGGTCCGTT
18S rRNA Human F- CGGCTACCACATCCAAGGAA
R- AGCTGGAATTACCGCGGC
ADAMTS-5 a disintegrin and MMP with thrombospondin motifs-5, MMP-13
matrix metalloproteinase-13, 18S rRNA 18S ribosomal RNA
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La Jolla, CA, USA). The threshold for statistical sig-
nificance was set at P <0.05. All values are displayed
as mean ± standard deviation.
Results
R-Ihh activates the hedgehog pathway but does not
stimulate ADAMTS-5 and MMP-13 expression in bovine
articular chondrocytes
Isolated primary bovine chondrocytes were stimulated
with r-Ihh for 24 hours to assess the effects of hedgehog
pathway activation on catabolic gene expression. Follow-
ing r-Ihh treatment, Gli1 and Ptch1 expression was in-
creased relative to the unstimulated control by a
magnitude of 4.5-fold (P ≤0.001) and 3.2-fold (P ≤0.01)
respectively (Fig. 1a). The expression of MMP-13 was
not significantly altered following r-Ihh treatment, how-
ever, a small but significant reduction in ADAMTS-5
expression was observed (0.5-fold, P ≤0.01) (Fig. 1b).
These results demonstrate that r-Ihh successfully acti-
vated the hedgehog pathway but did not upregulate cata-
bolic gene expression.
Hedgehog pathway modulation does not alter cartilage
degradation in bovine cartilage explants
The induction of mRNA does not always correlate with
catabolic effects, therefore the effect of hedgehog pathway
activation on cartilage degradation was directly investi-
gated in bovine cartilage explants. Explants were treated
with r-Ihh for 24, 48 and 72 hrs and cartilage degradation
monitored by measuring the release of sGAG into the cul-
ture media (Fig. 2a). No significant change in sGAG re-
lease was observed at any time point relative to the
untreated control. Consequently, there was no significant
difference in the cumulative sGAG release at the end of
the 72-hour culture period. Furthermore, no significant
effects on sGAG release were observed when the treat-
ment period was extended (Additional file 1: Figure S1).
The hedgehog pathway antagonist, cyclopamine, was
similarly administered to bovine cartilage explants to
examine the influence of endogenous basal hedgehog
signalling on matrix catabolism. Cyclopamine signifi-
cantly decreased sGAG release only at the 24–48 hour
time point (P <0.05), at every other time point cyclopa-
mine had no effect on sGAG release and there was no
significant difference in cumulative sGAG release at the
end of the 72-hour culture period (Fig. 2b). These results
indicate that both hedgehog pathway activation by r-Ihh
and inhibition by cyclopamine does not influence matrix
catabolism in bovine cartilage. Cell viability analysis fol-
lowing treatment showed that the majority of cells are
alive after the 72-day treatment period (Additional file 1:
Figure S2A), with r-Ihh and cyclopamine treatment
yielding similar cell viability as control (Additional file 1:
Figure S2b).
Hedgehog pathway activation has no effect on ADAMTS-
5 or MMP-13 expression or matrix catabolism in human
cartilage
The above studies were repeated using human chondro-
cytes and cartilage explants to examine whether the ab-
sence of a catabolic response to r-Ihh was due to the use
of bovine tissue. In isolated primary human chondro-
cytes, r-Ihh stimulation for either 24 or 72 hours did not
significantly alter ADAMTS-5 gene expression relative to
the untreated control (Fig. 3a and b). A significant 0.6-
fold reduction in MMP-13 expression was observed at
24 hours (P <0.05, Fig. 3a), however, by 72 hours this
was no longer significantly different to the control group
(Fig. 3b). Neither r-Ihh nor cyclopamine significantly al-
tered sGAG release in human cartilage explants (Fig. 3c).
Fig. 1 Hedgehog pathway activation does not increase the expression of a disintegrin and matrix metalloproteinase with thrombospondin motif
(ADAMTS-5) and matrix metalloproteinase-13 (MMP-13) in bovine articular chondrocytes. After 24 hours of stimulation with r-Ihh, changes in the
gene expression of (a) Gli1 and Ptch1 and (b) ADAMTS-5 and MMP-13 were measured. Data are mean fold-change normalised to untreated
controls with standard deviation error bars (n = 9 from three separate donors). *Statistically significant differences relative to untreated controls,
*P <0.05, **P ≤0.01, and ***P ≤0.001. r-Ihh recombinant Ihh
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Similar to bovine tissue, these results suggest that hedge-
hog signalling plays a minimal role in modulating extra-
cellular matrix catabolism in human articular cartilage.
Hedgehog pathway modulation does not affect IL-1β-
induced cartilage degradation in bovine cartilage
explants
Next, we sought to examine whether the previously re-
ported degradative effects of hedgehog signalling were
due to the presence of inflammatory cytokines in the
OA microenvironment. Bovine cartilage explants were
treated with 2.5 ng/mL IL-1β treatment for 24 hours. IL-
1β treatment resulted in a significant increase in sGAG
release over the 72-hour culture period compared to
untreated controls (P <0.01) (Fig. 4c). Following the
24-hour IL-1β treatment, explants displayed a 7.8-fold
increase in sGAG compared to untreated controls
(P <0.05) (Fig. 4a). Thereafter, sGAG release decreased at
each subsequent time point, with IL-1β-treated explants
displaying 2.8-fold and 1.3-fold increases relative to con-
trols at 48 and 72 hours, respectively, as the effects of the
single dose treatment wore off. To investigate whether IL-
1β influences the effect of hedgehog pathway activation
on cartilage degradation, we evaluated the effects of r-Ihh
and cyclopamine on sGAG release using this inflamma-
tory model. The release of sGAG over 72 hours was not
significantly modulated by the addition of r-Ihh (Fig. 4b)
or cyclopamine (Fig. 4c) compared to IL-1β treatment
alone. Additional antagonists, KAAD-cyclopamine, SANT-
1, and GANT61, all showed a similar trend with no signifi-
cant change in IL-1β-induced sGAG release at 72 hours
(Additional file 1: Figure S3). Taken together, these results
Fig. 2 Hedgehog pathway modulation does not influence cartilage degradation in bovine explants. The sulphated glycosaminoglycans (sGAG)
release for explants treated with r-Ihh (a) and cyclopamine (b) shown at 24-hour intervals and cumulatively over the 72-hour culture period as
compared to untreated controls. All data are displayed as mean sGAG release, normalised to the untreated controls at the same time point, with
standard deviation error bars (n = 9 from three separate donors). r-Ihh recombinant Ihh
Fig. 3 Hedgehog pathway activation has no effect on a disintegrin and matrix metalloproteinase with thrombospondin motif-5 (ADAMTS-5) and
matrix metalloproteinase-13 (MMP-13) gene expression or on sulphated glycosaminoglycans (sGAG) release in human articular cartilage. Changes
in the gene expression of ADAMTS-5 and MMP-13 in isolated human articular chondrocytes are shown after 24 hours (a) and 72 hours (b) of
stimulation with recombinant Indian hedgehog (r-Ihh) compared to controls. Data are mean fold-change (n = 12 from three separate donors). c sGAG
release for untreated controls, r-Ihh, and cyclopamine at 24-hour intervals over the 72-hour culture period, and cumulatively over the 72-hour culture
period. Data are mean sGAG release, normalised to the untreated controls from the same donor tissue at the same time point, with standard deviation
error bars (n = 6). *Statistically significant difference between groups and their respective untreated controls, *P <0.05, **P ≤0.01, and ***P ≤0.001
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indicate that the presence of IL-1β in this in vitro model of
inflammatory arthritis does not modify the catabolic re-
sponse to hedgehog pathway activation.
IL-1β suppresses hedgehog pathway activation in bovine
articular chondrocytes
Finally, we examined whether IL-1β influenced the acti-
vation of hedgehog signalling in response to the addition
of r-Ihh (Fig. 5). Treatment of isolated bovine chondro-
cytes with 10 ng/mL IL-1β inhibited r-Ihh-induced Gli1
(Fig. 5a) and Ptch1 (Fig. 5b) gene expression. Conversely,
we also observed that activation of hedgehog signalling
weakly downregulates IL-1β-induced ADAMTS-5 ex-
pression (Fig. 5c). These results suggest there is molecu-
lar crosstalk between the hedgehog and IL-1β signalling
pathways in chondrocytes.
Fig. 4 Hedgehog pathway modulation does not affect cartilage degradation in IL-1β-treated explants. a Changes in cumulative sulphated
glycosaminoglycans (sGAG) release following treatment with IL-1β, from 0 to 24 hours, in bovine articular cartilage explants are shown over the
72-hour culture period. b The mean cumulative sGAG release at 72 hours for explants treated with IL-1β in the presence or absence of recombinant
Indian hedgehog (r-Ihh) is displayed, compared to untreated controls. c Mean cumulative sGAG release at 72 hours for explants treated with IL-1β in
the presence or absence of cyclopamine, compared to untreated controls. All data are mean sGAG release, normalised to untreated controls from the
same animal at the same time point, with standard deviation error bars (n = 9 from three separate donors). *Statistically significant difference between
the treatment groups and their respective untreated control, *P <0.05, **P ≤0.01, and ***P ≤0.001
Fig. 5 IL-1β reduces hedgehog pathway activation in response to recombinant Indian hedgehog (r-Ihh). After 24 hours of treatment, in bovine
articular chondrocytes, IL-1β prevents upregulation in GLI1 (a) and PTCH1 (b) expression in response to r-Ihh treatment. c Treatment with IL-1β
similarly repressed r-Ihh upregulation of a disintegrin and matrix metalloproteinase with thrombospondin motif (ADAMTS-5) expression but did
not completely abolish this effect. *Statistically significant difference between the r-Ihh-treated samples and the untreated control; +statistically
significant difference between the r-Ihh/IL-1β-treated samples and the r-Ihh-treated samples (n = 9 from three separate donors), ***P ≤0.001,
++ P ≤0.01, and +++ P ≤0.001
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Discussion
In this study, we examined the effects of hedgehog signal-
ling on ADAMTS-5 and MMP-13 gene expression and
cartilage degradation in isolated chondrocytes and cartil-
age tissue, and in a well-established in vitro explant model
of inflammatory arthritis [19]. The efficacy of this IL-1β-
treatment protocol has been proven in our previous work,
which showed significant effects of IL-1β-treatment on a
number of parameters such as PGE2, NO, matrix degrad-
ation and biomechanical changes [19, 27–29]. Our work is
the first to illustrate that ligand-activation of chondrocyte
hedgehog signalling is unable to stimulate the expression
of the pro-catabolic genes ADAMTS-5 and MMP-13 or
directly induce cartilage matrix breakdown. We also
demonstrated that even in IL-1β treated explants, the
activation or inhibition of hedgehog signalling cascade
does not yield any significant effects on cartilage
matrix degradation.
As these studies are focused on examining ligand-
induced hedgehog signalling, the basal levels of hedge-
hog signalling was not measured in these studies. We
have, however, shown the induction of hedgehog signal-
ling via Ihh-induced upregulation of Gli1 and Ptch1
(Fig. 1a and Fig. 5a and b). Despite successful activation
of the hedgehog pathway, the expression of ADAMTS-5
and MMP-13 was not significantly altered by r-Ihh treat-
ment in bovine or human articular chondrocytes. This
lack of catabolic response to hedgehog signalling is an
apparent contrast to previous studies [26, 28]. These dif-
ferences, however, were not due to the loss of cellularity,
as shown by cell viability analysis, which was approxi-
mately 70 % in all groups including controls at the end
of the 72-hour treatment period. In previous studies,
hedgehog pathway activation was shown to upregulate
the expression of these catabolic genes downstream of
the transcription factor Runx2 [5]. It is therefore pos-
sible that the 24-hour treatment used in the current
study was not sufficient to regulate gene expression.
However, ADAMTS-5 and MMP-13 expression were not
significantly influenced by r-Ihh in human articular
chondrocytes following longer treatment for 72 hours ei-
ther. Hedgehog signalling also failed to stimulate matrix
catabolism in bovine cartilage explants. Similar results
were obtained for human cartilage explants, which, how-
ever, were taken from a single donor and therefore can
only be used as validation for bovine and isolated chon-
drocyte studies. Overall, these data indicate that hedge-
hog pathway activation by itself does not stimulate
cartilage degradation.
Our results may appear to be in contrast to previous
studies linking the hedgehog pathway to ADAMTS-5 and
MMP-13 expression. For example, Lin et al. demonstrated
that r-Ihh stimulation in human cartilage in OA increases
the expression of both ADAMTS-5 and MMP-13 [26].
Similarly, Zhou et al. demonstrated that surgically induced
OA in Ihh-deleted mice results in the decreased expres-
sion of MMP-13 [27]. However, to the best of our know-
ledge, this is the first study to examine the effect of Ihh on
ADAMTS-5 and MMP-13 expression in healthy chondro-
cytes, as opposed to the OA models used in previous stud-
ies where Ihh signalling deregulated the expression of
catabolic enyzmes [4–6, 9, 15, 17, 18, 30, 31]. Ihh signal-
ling has been described as “context-dependent” such that
it inhibits or promotes chondrocyte hypertrophy depend-
ing on the levels of parathyroid hormone-related protein
present [32]. It is thus possible that Ihh signalling may be
influenced by its interactions with the complex biochem-
ical milieu within cartilage in OA. It is possible however
that these alterations in hedgehog signalling may have
long-term effects that are not measurable in the time
course used in these studies. These include potential ef-
fects on chondrocyte fate, including an eventual deve-
lopment of chondrocyte hypertrophy and subsequent
upregulation in catabolic enzymes and the development of
osteoarthritic phenotype.
In healthy cartilage, Runx2 expression is inhibited dir-
ectly by HDAC4 and indirectly by transforming growth
factor-β (TGF-β), via Smads 2 and 3. Therefore two
plausible candidates for interaction are histone deacety-
lase 4 (HDAC4) and TGF-β [17, 33]. The inhibitory
effects of these proteins on Runx2 may prevent Ihh-
induced expression of Runx2 in healthy cartilage, which
would explain the lack of Ihh-induced ADAMTS-5 and
MMP-13 upregulation observed in the current study. In
OA, the levels of HDAC4 are decreased, relieving its
inhibition of Runx2. Similarly in OA, TGF-β activates
Smads 1, 5, and 8, which promote Runx2 expression
[17, 33]. It is in this context that Ihh may be able to con-
tribute to the upregulation of Runx2 and subsequent
ADAMTS-5- andMMP-13-mediated cartilage degradation
in the joints in OA.
In this study, we also examined the influence of hedge-
hog pathway activation in a well-established in vitro bo-
vine explant model of inflammatory arthritis [34]. We
have previously shown that IL-1β induces the trafficking
of key signalling proteins onto primary cilia with an as-
sociated increase in cilia length [27–29]. As hedgehog
signalling in chondrocytes also requires ciliary traffick-
ing, we hypothesised that IL-1β synergises the catabolic
response to hedgehog ligand through modulation of the
primary cilium. This model is based on the pro-
inflammatory cytokine, IL-1β, which is upregulated in
inflammatory arthritis and causes cartilage degradation
[19, 20, 35, 36]. Although there are numerous factors
that contribute to the development of OA, including
pathological increases in other cytokines, injurious
mechanical loading, increased wnt signalling etc., it is
challenging to incorporate all these factors into a single
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in vitro model. Bovine cartilage explants were treated
with 2.5 ng/mL of IL-1β from 0–24 hours and then
treated with normal chondrocyte media for the remain-
der of the 72-hour culture period (Fig. 4). While higher
than the long-term pathological concentrations of IL-1β
measured within the joints in OA [34, 37], the dosing
strategy used in the current study aimed to strike a bal-
ance between having a sufficiently high IL-1β dose to in-
duce detectable levels of matrix degradation over a short
period of time without overshadowing the possible cata-
bolic effects of hedgehog signalling. IL-1β treatment in-
creased cartilage degradation throughout the 72-hour
culture period compared to untreated controls; this was
not influenced by treatment with r-Ihh. In addition, the
hedgehog antagonists, cyclopamine, KAAD-cyclopamine,
SANT-1, and GANT61, did not display any significant in-
hibition of IL-1β-induced cartilage damage, despite previ-
ous reports suggesting a potential therapeutic role for
hedgehog blockade in arthritis [4–6]. Thus, these data
show no synergistic interaction between the catabolic ef-
fects of hedgehog signalling and IL-1β.
Finally, we showed that in IL-1β-treated chondrocytes,
the upregulation of Gli1 and Ptch1 in response to r-Ihh is
greatly reduced. We also showed that IL-1β induces an up-
regulation in ADAMTS5 expression, which was signifi-
cantly reduced but not abolished by Ihh-treatment. We
suggest that this is due to the increase in primary cilia
length with IL-1β treatment [28] as our recent studies show
an inverse relationship between cilia length and hedgehog
signalling [9, 38]. The mechanism for reduced hedgehog
signalling may be due to reduced intraflagellar transport
[28, 39] and changes in ciliary trafficking [29, 40].
Conclusion
Previous studies report that an aberrant upregulation of
hedgehog signalling occurs in OA, leading to cartilage
degradation [4–6]. However, this study showed for the
first time that in healthy cartilage in vitro, hedgehog
pathway activation by itself does not cause cartilage deg-
radation. We therefore examined whether the presence
of inflammatory cytokines stimulated hedgehog-induced
catabolism. However, even in the presence of IL-1β, nei-
ther hedgehog agonists nor antagonists had any effect
on matrix degradation. Thus, we suggest that the re-
ported role of hedgehog signalling in matrix catabolism
in OA must be due to a complex interaction with other
pathological factors or more long-term effects on chon-
drocyte fate. Importantly, we demonstrated that IL-1β
suppresses hedgehog pathway activation by r-Ihh there-
fore any possible effects of hedgehog signalling in OA
are likely to be downregulated by the presence of inflam-
matory cytokines. We conclude that chondrocyte hedge-
hog signalling is not catabolic in otherwise healthy
cartilage and is in fact downregulated by inflammatory
cytokines, such that any role for hedgehog is extremely
context-dependent.
Additional file
Additional file 1: Figure S1. Hedgehog pathway activation over 6 days
does not influence cartilage degradation. Changes in sulphated
glycosaminoglycans (sGAG) release following treatment with IL-1β or
recombinant Indian hedgehog (r-Ihh), in bovine articular cartilage explants,
over a 6-day culture period. Although IL-1β increased sGAG release into the
media over the 6-day culture period, there was no upregulation in sGAG in
response to r-Ihh treatment (n = 6 from three separate donors). Figure S2.
Treatment with r-Ihh or cyclopamine had no effect on chondrocyte viability.
a Representative fluorescence microscopy image showing live cells (calcein
AM/green) and dead cells (ethidium homodimer/red) within a cartilage
explant. Scale bar represents 50 μm. Arrows indicate the articular surface.
b Percentage cell viability. Values represent mean with error bars showing
standard deviations (n = 9 from three separate donors). Figure S3. Hedgehog
pathway antagonists KAAD-cyclopamine, SANT-1, and GANT61 do not
inhibit cartilage degradation in IL-1β-treated explants. Following treatment
with IL-1β for 24 hours, bovine cartilage explants exhibit an increase in
cumulative sGAG release after 72 hours compared to untreated controls,
however, the hedgehog antagonists KAAD-cyclopamine, SANT-1, and
GANT61 did not significantly modulate the effects of IL-1β. All data are
mean sGAG release, normalised to untreated controls from the same animal
at the same time point (n = 9 from three separate donors). *Statistically
significant difference, *P < 0.05, **P ≤0.01, and ***P ≤0.001. (DOCX 1215 kb)
Abbreviations
ACAN: aggrecan gene; ADAMTS: a disintegrin and matrix metalloproteinase with
thrombospondin motif; BSA: bovine serum albumin; COL2A1: type II collagen
gene; COX-2: prostaglandin E2 producing enzyme; DMEM: Dulbecco’s modified
Eagle’s medium; DMMB: dimethymethylene blue; FBS: foetal bovine serum;
HDAC4: histone deacetylase 4; Ihh: Indian hedgehog; IL-1β: interleukin-1β;
iNOS: nitric oxide producing enzyme; MMP: matrix metalloproteinase; NO: nitric
oxide; OA: osteoarthritis; PBS: phosphate-buffered saline; PGE2: prostaglandin E2;
Ptch1: patched 1; r-Ihh: recombinant Ihh; Runx2: runt-related transcription factor 2;
sGAG: sulphated glycosaminoglycans; Smo: Smoothened; TGFβ: transforming
growth factor β.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CT conducted isolated chondrocyte as well as the human explant experiments
and helped in drafting the manuscript. RP conducted the bovine explant
experiments and drafted the manuscript. TK assisted with the bovine explant
experiments and provided substantial editing of the manuscript. AW, JC, CH,
and MK provided the conceptual framework for these studies and editing for
the manuscript. All authors were involved in data analysis and read and
approved the final manuscript.
Acknowledgements
AW and TK were funded on an Arthritis Research UK (3514) project grant.
CT was funded on an AO Foundation (S-12-15 K) project grant and is now
on an MRC (MR/L002876/1) project grant. RP conducted the work as part of
an intercalated BSc in Biomedical Engineering & Clinical Materials.
Author details
1Institute of Bioengineering and School of Engineering and Material Sciences,
Queen Mary University of London, Mile End Road, London E1 4NS, UK. 2Center
for Endocrinology, William Harvey Research Institute, School of Medicine and
Dentistry, Queen Mary University of London, London, UK. 3Department of
Biomedical Engineering, Columbia University, New York, NY, USA. 4Kennedy
Institute of Rheumatology, University of Oxford, Oxford, UK.
Received: 7 September 2015 Accepted: 8 December 2015
Thompson et al. Arthritis Research & Therapy  (2015) 17:373 Page 8 of 9
References
1. Sandell LJ, Aigner T. Articular cartilage and changes in arthritis. An
introduction: cell biology of osteoarthritis. Arthritis Res. 2001;3(2):107–13.
2. Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease? Joint Bone
Spine. 2013;80(6):568–73.
3. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not
osteoarthrosis!). Osteoarthritis Cartilage. 2013;21(1):16–21.
4. Wei F, Zhou J, Wei X, Zhang J, Fleming BC, Terek R, et al. Activation of Indian
hedgehog promotes chondrocyte hypertrophy and upregulation of MMP-13
in human osteoarthritic cartilage. Osteoarthritis Cartilage. 2012;20(7):755–63.
5. Lin AC, Seeto BL, Bartoszko JM, Khoury MA, Whetstone H, Ho L, et al.
Modulating hedgehog signaling can attenuate the severity of osteoarthritis.
Nat Med. 2009;15(12):1421–5.
6. Zhou J, Chen Q, Lanske B, Fleming BC, Terek R, Wei X, et al. Disrupting the Indian
hedgehog signaling pathway in vivo attenuates surgically induced osteoarthritis
progression in Col2a1-CreERT2. Ihhfl/fl mice Arthritis Res Ther. 2014;16(1):R11.
7. Corbit KC, Aanstad P, Singla V, Norman AR, Stainier DY, Reiter JF. Vertebrate
Smoothened functions at the primary cilium. Nature. 2005;437(7061):1018–21.
8. Rohatgi R, Milenkovic L, Scott MP. Patched1 regulates hedgehog signaling
at the primary cilium. Science. 2007;317(5836):372–6.
9. Thompson CL, Chapple JP, Knight MM. Primary cilia disassembly down-regulates
mechanosensitive hedgehog signalling: a feedback mechanism controlling
ADAMTS-5 expression in chondrocytes. Osteoarthritis Cartilage. 2014;22(3):490–8.
10. Huangfu D, Liu A, Rakeman AS, Murcia NS, Niswander L, Anderson KV.
Hedgehog signalling in the mouse requires intraflagellar transport proteins.
Nature. 2003;426(6962):83–7.
11. Buttitta L, Mo R, Hui CC, Fan CM. Interplays of Gli2 and Gli3 and their
requirement in mediating Shh-dependent sclerotome induction.
Development. 2003;130(25):6233–43.
12. St-Jacques B, Hammerschmidt M, McMahon AP. Indian hedgehog signaling
regulates proliferation and differentiation of chondrocytes and is essential
for bone formation. Genes Dev. 1999;13(16):2072–86.
13. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ.
Regulation of rate of cartilage differentiation by Indian hedgehog and
PTH-related protein. Science. 1996;273(5275):613–22.
14. van der Kraan PM, van den Berg WB. Chondrocyte hypertrophy and
osteoarthritis: role in initiation and progression of cartilage degeneration?
Osteoarthritis Cartilage. 2012;20(3):223–32.
15. Zhang C, Wei X, Chen C, Cao K, Li Y, Jiao Q, et al. Indian hedgehog in
synovial fluid is a novel marker for early cartilage lesions in human knee
joint. Int J Mol Sci. 2014;15(5):7250–65.
16. Shimoyama A, Wada M, Ikeda F, Hata K, Matsubara T, Nifuji A, et al. Ihh/Gli2
signaling promotes osteoblast differentiation by regulating Runx2
expression and function. Mol Biol Cell. 2007;18(7):2411–8.
17. Cao K, Wei L, Zhang Z, Guo L, Zhang C, Li Y, et al. Decreased histone
deacetylase 4 is associated with human osteoarthritis cartilage degeneration
by releasing histone deacetylase 4 inhibition of runt-related transcription
factor-2 and increasing osteoarthritis-related genes: a novel mechanism of
human osteoarthritis cartilage degeneration. Arthritis Res Ther. 2014;16(6):491.
18. Tchetina EV, Squires G, Poole AR. Increased type II collagen degradation and
very early focal cartilage degeneration is associated with upregulation of
chondrocyte differentiation related genes in early human articular cartilage
lesions. J Rheumatol. 2005;32(5):876–86.
19. Wann AK, Mistry J, Blain EJ, Michael-Titus AT, Knight MM. Eicosapentaenoic
acid and docosahexaenoic acid reduce interleukin-1beta-mediated cartilage
degradation. Arthritis Res Ther. 2010;12(6):R207.
20. Wang SN, Xie GP, Qin CH, Chen YR, Zhang KR, Li X, et al. Aucubin prevents
interleukin-1 beta induced inflammation and cartilage matrix degradation
via inhibition of NF-kappaB signaling pathway in rat articular chondrocytes.
Int Immunopharmacol. 2015;24(2):408–15.
21. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by
direct binding of cyclopamine to Smoothened. Genes Dev. 2002;16(21):2743–8.
22. Li R, Cai L, Ding J, Hu CM, Wu TN, Hu XY. Inhibition of hedgehog signal pathway
by cyclopamine attenuates inflammation and articular cartilage damage in rats
with adjuvant-induced arthritis. J Pharm Pharmacol. 2015;67(7):963–71.
23. Rohatgi R, Milenkovic L, Corcoran RB, Scott MP. Hedgehog signal
transduction by Smoothened: pharmacologic evidence for a 2-step
activation process. Proc Natl Acad Sci U S A. 2009;106(9):3196–201.
24. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB.
Hedgehog signalling within airway epithelial progenitors and in small-cell
lung cancer. Nature. 2003;422(6929):313–7.
25. Chowdhury TT, Bader DL, Lee DA. Dynamic compression inhibits the synthesis
of nitric oxide and PGE(2) by IL-1beta-stimulated chondrocytes cultured in
agarose constructs. Biochem Biophys Res Commun. 2001;285(5):1168–74.
26. Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay
for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res.
1982;9(4):247–8.
27. Wann AK, Chapple JP, Knight MM. The primary cilium influences interleukin-
1beta-induced NFkappaB signalling by regulating IKK activity. Cell Signal.
2014;26(8):1735–42.
28. Wann AK, Knight MM. Primary cilia elongation in response to interleukin-1
mediates the inflammatory response. Cell Mol Life Sci. 2012;69(17):2967–77.
29. Wann AK, Thompson CL, Chapple JP, Knight MM. Interleukin-1beta sequesters
hypoxia inducible factor 2alpha to the primary cilium. Cilia. 2013;2(1):17.
30. Alman BA. The role of hedgehog signalling in skeletal health and disease.
Nat Rev Rheumatol. 2015;11(9):552–60.
31. Zhou J, Wei X, Wei L. Indian Hedgehog, a critical modulator in osteoarthritis,
could be a potential therapeutic target for attenuating cartilage
degeneration disease. Connect Tissue Res. 2014;55(4):257–61.
32. Mak KK, Kronenberg HM, Chuang PT, Mackem S, Yang Y. Indian hedgehog
signals independently of PTHrP to promote chondrocyte hypertrophy.
Development. 2008;135(11):1947–56.
33. van der Kraan PM, Blaney Davidson EN, Blom A, van den Berg WB. TGF-beta
signaling in chondrocyte terminal differentiation and osteoarthritis:
modulation and integration of signaling pathways through receptor-Smads.
Osteoarthritis Cartilage. 2009;17(12):1539–45.
34. Kokebie R, Aggarwal R, Lidder S, Hakimiyan AA, Rueger DC, Block JA, et al.
The role of synovial fluid markers of catabolism and anabolism in
osteoarthritis, rheumatoid arthritis and asymptomatic organ donors. Arthritis
Res Ther. 2011;13(2):R50.
35. Qin J, Shang L, Ping AS, Li J, Li XJ, Yu H, et al. Response to ‘TNF/TNFR signal
transduction pathway-mediated anti-apoptosis and anti-inflammatory
effects of sodium ferulate on IL-1beta-induced rat osteoarthritis
chondrocytes in vitro’– authors’ reply. Arthritis Res Ther. 2013;15(3):409.
36. Stabellini G, De Mattei M, Calastrini C, Gagliano N, Moscheni C, Pasello M,
et al. Effects of interleukin-1beta on chondroblast viability and extracellular
matrix changes in bovine articular cartilage explants. Biomed Pharmacother.
2003;57(7):314–9.
37. McNulty AL, Rothfusz NE, Leddy HA, Guilak F. Synovial fluid concentrations
and relative potency of interleukin-1 alpha and beta in cartilage and
meniscus degradation. J Orthop Res. 2013;31(7):1039–45.
38. Prodromou NV, Thompson CL, Osborn DP, Cogger KF, Ashworth R, Knight
MM, et al. Heat shock induces rapid resorption of primary cilia. J Cell Sci.
2012;125(Pt 18):4297–305.
39. Wang Y, Zhou Z, Walsh CT, McMahon AP. Selective translocation of
intracellular Smoothened to the primary cilium in response to Hedgehog
pathway modulation. Proc Natl Acad Sci U S A. 2009;106(8):2623–8.
40. Larkins CE, Aviles GD, East MP, Kahn RA, Caspary T. Arl13b regulates
ciliogenesis and the dynamic localization of Shh signaling proteins. Mol Biol
Cell. 2011;22(23):4694–703.
41. Stanton BZ, Peng LF. Small-molecule modulators of the Sonic Hedgehog
signaling pathway. Mol Biosyst. 2010;6(1):44–54.
42. Kim J, Hsia EY, Kim J, Sever N, Beachy PA, Zheng X. Simultaneous
measurement of smoothened entry into and exit from the primary cilium.
PLoS One. 2014;9(8):e104070.
43. Wang C, Wu H, Evron T, Vardy E, Han GW, Huang XP, et al. Structural basis
for Smoothened receptor modulation and chemoresistance to anticancer
drugs. Nat Commun. 2014;5:4355.
44. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA. Small molecule modulation
of Smoothened activity. Proc Natl Acad Sci U S A. 2002;99(22):14071–6.
45. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated
transcription and tumor cell growth by small-molecule antagonists.
Proc Natl Acad Sci U S A. 2007;104(20):8455–60.
46. Mazumdar T, Devecchio J, Agyeman A, Shi T, Houghton JA. Blocking
Hedgehog survival signaling at the level of the GLI genes induces DNA
damage and extensive cell death in human colon carcinoma cells. Cancer
Res. 2011;71(17):5904–14.
Thompson et al. Arthritis Research & Therapy  (2015) 17:373 Page 9 of 9
